IP Library › Granted Patent US 12,410,128
Granted Patent B1
US 12,410,128 · App. 18/134,724 · Granted Sep 9, 2025

Therapeutic alkaloid compounds

Inventor: Jacob M. Hooker (Winchester, MA)
Assignee: Sensorium Therapeutics, Inc.
C07D209/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,128
App. No.
18/134,724
Granted
Sep 9, 2025
Kind
B1
Abstract

Disclosed are compounds that are derivatives of mesembrine or mesembrenone, and related methods of preparing and using these compounds.

Claims (29)

1. A compound of Formula (IB):

or a pharmaceutically acceptable salt thereof; wherein

R 1 is halo;

R 2 is methyl or halomethyl;

R 3 is methyl, halomethyl, or benzyl; and

m is 1, 2, or 3.

2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of Formula (IB-2):

3. The compound of claim 2 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl; and R 3 is methyl.

4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl; and R 3 is methyl.

5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2 is methyl optionally substituted with one or more fluoro; and R 3 is methyl optionally substituted with one or more fluoro.

6. The compound of claim 1 , selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is

8. A compound of Formula (IB-1):

or a pharmaceutically acceptable salt thereof; wherein

R 1 is halo;

R 2 is methyl or halomethyl;

R 3 is methyl, halomethyl, or benzyl; and

m is 1, 2, or 3.

9. The compound of claim 8 , wherein the compound is a compound of Formula I (IB-4) or a pharmaceutically acceptable salt thereof:

(IB-4).

10. The compound of claim 9 , wherein R 1 is iodo.

11. The compound of claim 9 , wherein R 1 is bromo.

12. The compound of claim 9 , wherein R 1 is fluoro.

13. The compound of claim 12 , wherein R 2 is methyl.

14. The compound of claim 13 , wherein R 3 is methyl.

15. The compound of claim 8 , wherein R 1 is fluoro, chloro, bromo, or iodo.

16. The compound of claim 15 , wherein R 2 is methyl.

17. The compound of claim 16 , wherein R 3 is methyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2023
From: HOOKER, JACOB M.
To: SENSORIUM THERAPEUTICS, INC.
Reel/Frame 063944/0104 →
Continuity (2)
Provisional Application 63452267 · Mar 15, 2023
Provisional Application 63331428 · Apr 15, 2022
References Cited (45)
US 6288104B1 · Gericke et al. · 2001 [cited by applicant]
US 8552051B2 · Harvey et al. · 2013 [cited by applicant]
US 8865723B2 · Gurney et al. · 2014 [cited by applicant]
US 8980338B2 · Gericke et al. · 2015 [cited by applicant]
US 9381220B2 · Gericke et al. · 2016 [cited by applicant]
US 10864239B1 · Bytton · 2020 [cited by applicant]
US 11173142B2 · Davies · 2021 [cited by applicant]
CN 102000069A · 2011 [cited by applicant]
CN 102153501A · 2011 [cited by applicant]
CN 113072576A · 2021 [cited by applicant]
WO WO1997046234A1 · 1997 [cited by applicant]
WO WO2005051381A1 · 2005 [cited by examiner]
WO WO2006050057A2 · 2006 [cited by applicant]
WO WO2010106494A1 · 2010 [cited by applicant]
WO WO2010106495A1 · 2010 [cited by applicant]
WO WO2014155351A1 · 2014 [cited by applicant]
WO WO2015048590A1 · 2015 [cited by applicant]
WO WO2016049595A1 · 2016 [cited by applicant]
WO WO2016157045A1 · 2016 [cited by applicant]
WO WO2021086345A1 · 2021 [cited by applicant]
WO WO2022140417A1 · 2022 [cited by applicant]
WO WO2023004428A1 · 2023 [cited by applicant]
WO WO2023069455A1 · 2023 [cited by applicant]
Rehman et al., In Silico, Ex Vivo and In Vivo Studies of Roflumilast as a Potential Antidiarrheal and Antispasmodic agent: Inhibition of the PDE-4 Enzyme and Voltage-gated Ca++ ion Channels, Molecules, Feb. 24, 2020, vo… [cited by examiner]
Harvey et al., Pharmacological actions of the South African medicinal and functional food plant [cited by examiner]
Meyer et al., GC-MS, LC-MS n, LC-high resolution-MS n, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high “Kanna” isolated from Sceletium t… [cited by examiner]
Patani et al., Bioisosterism: A Rational Approach in Drug Design, Chemical Reviews, 1996, vol. 96(8), pp. 3147-3175 (Year: 1996). [cited by examiner]
Dimpfel et al., “Effect of Zembrin and four of its alkaloid constituents on electric excitability of the rat hippocampus,” Journal of Ethnopharmacology, 223: pp. 135-141 (2018). [cited by applicant]
Gericke et al., “Sceletium—A review update,” Journal of Ethnopharmacology, 119: 653-663 (2008). [cited by applicant]
Harvey et al., “Pharmacological actions of the South African medicinal and functional food plant [cited by applicant]
Jeffs et al., “Late stages in the biosynthesis of mesembrine: sceletenone as a precursor to the cis-3a-(3, 4-dimethoxyphenyl) octahydroindole alkaloids”, [cited by applicant]
Jeffs et al., “Sceletium alkaloids. Structures of five new bases from Sceletium namaquens”. [cited by applicant]
Krstenansky., “Mesembrine alkaloids: Review of their occurrence, chemistry, and pharmacology,” Journal of Ethnopharmacology, 195: 10-19 (2017). [cited by applicant]
Loria et al., “Effects of Sceletium tortuosum in rats,” Journal of Ethnopharmacology, 155: pp. 731-735 (2014). [cited by applicant]
Luo et al., “A network pharmacology-based approach to explore the therapeutic potential of Sceletium tortuosum in the treatment of neurodegenerative disorders,” PLOS One, 17(8): 21 pages (2022). [cited by applicant]
Maphanga et al., “Mesembryanthemum tortuosum L. alkaloids modify anxiety-like bahaviour in a zebrafish model,” Journal of Ethnopharmacology, 290: 13 pages (2022). [cited by applicant]
Meyer et al., “GC-MS, LC-MS n, LC-high resolution-MS n, and NMR studies on the metabolism and toxicological detection of mesembrine and mesembrenone, the main alkaloids of the legal high “Kanna” isolated from Sceletium … [cited by applicant]
Murbach et al., “A toxicological safety assessment of a standardized extract of Sceletium tortuosum (Zembrin) in rats,” Food and Chemical Toxicology, 74: pp. 190-199 (2014). [cited by applicant]
Nell et al., “A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of Extract Sceletium tortuosum (Zembrin) in Healthy Adults,” The Journal of Alternative and Complementary Medicine, 19(11): 898-904 (201… [cited by applicant]
Olatunji et al., “Sceletium tortuosum: A review on its phytochemistry, pharmacokinetics, biological, pre-clinical and clinical activities,” Journal of Ethnopharmacology, 287 (2022) Article 114711, pp. 1-16. [cited by applicant]
Patnala et al., “Medicinal use of Sceletium: Characterization of Phytochemical Components of Sceletium Plant Species using HPLC with UV and Electrospray Ionization—Tandem Mass Spectroscopy,” J Pharm Pharm Sci, 18(4): 41… [cited by applicant]
Patnala, “Pharmaceutical Analysis and Quality of Complementary Medicines: Sceletium and Associated Products,” Sceletium Review Thesis, Rhodes University: 251 pages (2007). [cited by applicant]
Richter et al., “PDE4 as a target for cognition enhancement,” Expert Opin Ther Targets, 17(9): pp. 1011-1027 (2013). [cited by applicant]
Roscher et al., “Forensic analysis of mesembrine alkaloids in S celetium tortuosum by nonaqueous capillary electrophoresis mass spectrometry”, [cited by applicant]
Terburg et al., “Acute Effects of Sceletium tortuosum (Zembrin), a Dual 5-HT Reuptake and PDE4 Inhibitor, in the Human Amygdala and its Connection to the Hypothalamus,” Neuropsychopharmacology, 38: 2708-2716 (2013). [cited by applicant]